Key Facts Although the drugs were first approved for Type 2 diabetes maintenance, they were approved for weight loss in recent years, and research has shown they cause significant results: Tirzepatide typically causes patients to lose an average of 22.5% of body fat, while semaglutide causes a 15% reduction
The answer depends on multiple factors, including weight loss goals, comorbidities, patient preferences, cost considerations, and tolerance for different side effect profiles
A large prospective cohort study that tracked over 1,700 patients demonstrated that patients who underwent a Roux-en-Y gastric bypass lost an excess 21% of their body mass normalized to their non-surgical matched controls at the 10 year point (corresponding to 35 kg (~77 lbs) greater weight loss)
The search for a solution to this problem has led researchers and clinicians to explore combination protocols that address both fat reduction and muscle preservation simultaneously
I thought Id be an actress or ballerina, but I had to take a science class and that one sounded cool, and I absolutely was a fish in water
monitor for flare-ups and adjust
